GlassScriptPhysician profile
Kara Austin
NPI 1003477449
$1,584.82
in general payments reported to CMS, 2019-2025
19 companies · $592 in 2025
The $592 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $257 · 2022: $140 · 2023: $123 · 2024: $472 · 2025: $592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,187.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $281.46 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $278.22 | 2024-2025 | |
| Ardelyx, INC. | $160.93 | 2024-2025 | Ibsrela |
| Astrazeneca Pharmaceuticals LP | $132.83 | 2022-2024 | Farxiga, Lokelma |
| Pfizer INC. | $123.42 | 2021 | |
| Fresenius USA Marketing, INC. | $79.84 | 2024-2025 | Velphoro, Velphoro |
| Bard Peripheral Vascular, INC. | $77.95 | 2025 | Rotarexs 6 F X 135 Cm |
| Insmed, INC. | $75.80 | 2022 | |
| Janssen Pharmaceuticals, INC | $68.62 | 2021 | |
| Calliditas Therapeutics US INC. | $45.24 | 2024-2025 | Tarpeyo |
| Abbvie INC. | $42.66 | 2021-2023 | |
| Astellas Pharma US INC | $41.09 | 2021 | |
| Edwards Lifesciences Corporation | $36.51 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.30 | 2023 | Jardiance |
| Travere Therapeutics, INC. | $31.83 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $20.94 | 2024 | Jynarque |
| Boston Scientific Corporation | $20.64 | 2025 | Farapulse |
| Akebia Therapeutics INC | $20.41 | 2024 | Auryxia |
| Alexion Pharmaceuticals, INC. | $14.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Austin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.